Abstract:The use of psychostimulants and alcohol disrupts blood-brain barrier (BBB) integrity, resulting in alterations to cellular function, and contributes to neurotoxicity. The BBB is the critical boundary of the central nervous system (CNS) where it maintains intracellular homeostasis and facilitates communication with the peripheral circulation. The BBB is regulated by tight junction (TJ) proteins that closely interact with endothelial cells (EC). The complex TJ protein network consists of transmembrane proteins, … Show more
“…Surprisingly, we discovered that all of the predicted upstream regulators that were inhibited have key roles in the regulation of the vasculature, including KLF2 (20), NRAS (21), and PTEN (22) (Figure 2d). These findings suggest that vascular integrity may be compromised in DLPFC of OUD subjects, in line with growing evidence that the blood brain barrier (BBB) is eroded as consequence of repeated opioid use (23,24).…”
Section: Enrichment Of Differentially Expressed Transcripts Involved supporting
Prevalence rates of opioid use disorder (OUD) have increased dramatically, accompanied by a surge of overdose deaths. While opioid dependence has been extensively studied in preclinical models, we still have a very limited understanding of the biological changes that occur in the brains of people who chronically use opioids and who are diagnosed with OUD. To address this, we conducted the largest transcriptomics study to date using postmortem brains from subjects with OUD. We focused on the dorsolateral prefrontal cortex (DLPFC) and nucleus accumbens (NAc), two regions heavily implicated in OUD. We discovered a high degree of overlap in transcripts between DLPFC and NAc in OUD, primarily associated with neuroinflammation. Moreover, additional transcripts were enriched for factors that control pro-inflammatory cytokine-mediated signaling and remodeling of the extracellular matrix (ECM). Our results also implicate a role for microglia as a critical driver for opioid-induced neuroplasticity. Overall, our findings reveal new connections between the brain’s immune system and opioid dependence in the human brain.
“…Surprisingly, we discovered that all of the predicted upstream regulators that were inhibited have key roles in the regulation of the vasculature, including KLF2 (20), NRAS (21), and PTEN (22) (Figure 2d). These findings suggest that vascular integrity may be compromised in DLPFC of OUD subjects, in line with growing evidence that the blood brain barrier (BBB) is eroded as consequence of repeated opioid use (23,24).…”
Section: Enrichment Of Differentially Expressed Transcripts Involved supporting
Prevalence rates of opioid use disorder (OUD) have increased dramatically, accompanied by a surge of overdose deaths. While opioid dependence has been extensively studied in preclinical models, we still have a very limited understanding of the biological changes that occur in the brains of people who chronically use opioids and who are diagnosed with OUD. To address this, we conducted the largest transcriptomics study to date using postmortem brains from subjects with OUD. We focused on the dorsolateral prefrontal cortex (DLPFC) and nucleus accumbens (NAc), two regions heavily implicated in OUD. We discovered a high degree of overlap in transcripts between DLPFC and NAc in OUD, primarily associated with neuroinflammation. Moreover, additional transcripts were enriched for factors that control pro-inflammatory cytokine-mediated signaling and remodeling of the extracellular matrix (ECM). Our results also implicate a role for microglia as a critical driver for opioid-induced neuroplasticity. Overall, our findings reveal new connections between the brain’s immune system and opioid dependence in the human brain.
“…A relevant illustration of this latter point would be the use of cationic nanoparticles which have long been demonstrated to disrupt the BBB, hence inducing neurotoxicity; consequently, the effect on the BBB integrity should be automatically assessed when dealing with this type of nanoformulation [21]. The same goes for certain classes of agents, such as psychostimulants or alcohol, which are known to alter the BBB integrity, resulting in neuroinflammation and subsequent toxicity [22]. Above all, drug development for CNS disorders is confronted with an additional major hurdle, regarding how to get therapies past the BBB.…”
The complexity and organization of the central nervous system (CNS) is widely modulated by the presence of the blood–brain barrier (BBB) and the blood–cerebrospinal fluid barrier (BCSFB), which both act as biochemical, dynamic obstacles impeding any type of undesirable exogenous exchanges. The disruption of these barriers is usually associated with the development of neuropathologies which can be the consequence of genetic disorders, local antigenic invasions, or autoimmune diseases. These disorders can take the shape of rare CNS-related diseases (other than Alzheimer’s and Parkinson’s) which a exhibit relatively low or moderate prevalence and could be part of a potential line of treatments from current nanotargeted therapies. Indeed, one of the most promising therapeutical alternatives in that field comes from the development of nanotechnologies which can be divided between drug delivery systems and diagnostic tools. Unfortunately, the number of studies dedicated to treating these rare diseases using nanotherapeutics is limited, which is mostly due to a lack of interest from industrial pharmaceutical companies. In the present review, we will provide an overview of some of these rare CNS diseases, discuss the physiopathology of these disorders, shed light on how nanotherapies could be of interest as a credible line of treatment, and finally address the major issues which can hinder the development of efficient therapies in that area.
“…Clinical and radiographic syndromes that overlap with PRES have been described in overdoses of drugs of abuse like benzodiazepines, amphetamines, and opiates. Drugs of abuse increase blood-brain barrier permeability, which, in turn, increases the influx of peripheral toxins into the brain [11,12]. Protein disruption at tight junctions, neuroinflammation, oxidative stress, and production of reactive oxygen species have all been postulated as fundamental mechanisms through which drugs alter the blood-brain barrier structure and integrity.…”
Section: Introductionmentioning
confidence: 99%
“…Heroin's effects indirectly involve its metabolites (morphine and 6-MAM) that act as substrates in P-glycoprotein membrane regulation. Pglycoprotein inhibition at the blood-brain barrier acutely disrupts the blood-brain barrier permeability and selectivity in the nucleus accumbens [11,12]. Cases of toxic leukoencephalopathy have been reported in patients with illicit heroin vapor inhalation [13][14][15][16].…”
Posterior Reversible Encephalopathy Syndrome (PRES) is a characteristic clinical radiographic syndrome with diffuse structural alteration of cerebral white matter secondary to myelin damage with diverse and multifactorial etiologies. It can present with acutely altered mentation, somnolence or occasionally stupor, vision impairment, seizures, and sudden or chronic headaches that are not focal. The pathophysiology remains unclear, but mechanisms involving endothelial injury and dysregulation of cerebral autoregulation have been purported. We report the case of a 36-year-old male with a history of heroin use disorder, who was admitted to our hospital for opioid withdrawal. CT head without contrast and MRI with and without gadolinium showed significant white matter disease in both cerebral hemispheres and cerebellum. He was diagnosed with Posterior Reversible Encephalopathy Syndrome secondary to heroin use and managed on the medical floor in collaboration with the neurology team. His clinical symptoms improved and he was discharged after six weeks. To our knowledge, this case did not present with the risk factors for PRES reported in the literature. For patients with heroin use disorder who present with an altered mental status, PRES should be highly suspected. The diagnosis and management require collaboration between psychiatry and neurology.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.